Clinical Trial Update: Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial assessing the effects of dapagliflozin on metabolic syndrome, insulin sensitivity, and insulin secretion; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: University of Guadalajara | Conditions: Metabolic Syndrome X | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-10-08